In July 2023, Raytec Biotechnology teamed up with Capricornia Contact Lens Pty Ltd from Australia to establish a joint venture called Epicon (Chengdu) Medical Technology Co., Ltd. in Wenjiang, Chengdu. Epicon will serve as a platform for comprehensive cooperation between Raytec Biotechnology and Capricornia in the field of ophthalmology, with a registered capital of 22.73 million yuan. It is a provider of innovative solutions for medical equipment in the field of ophthalmology, mainly involving the prevention and control of adolescent myopia, adult vision correction and treatment of ocular surface diseases, and a complete set of contact lens care products.
Epicon (Chengdu) Medical Technology Co., Ltd. will be established as the largest research and production base for ophthalmic regenerative medical materials in China, which is mainly operated by Ruitai Biotechnology, a wholly-owned subsidiary of Raytec Biotechnology. The base has a basic area of 70000 square meters, including a production building of 30000 square meters, a research and development building of 20000 square meters, an administrative building of 10000 square meters, and supporting facilities of 10000 square meters. It has unique advantages such as convenient transportation, good terrain, beautiful scenery, talent gathering, and complete supporting facilities.
Relying on Capricornia Contacts Lens Pty Ltd's internationally advanced optometry product research and development technology, and with the strong financial, venue, and personnel support of Raytec Biotechnology, Epicon will establish an internationally advanced product registration and production management system, a mature product marketing network, and achieve complementary advantages between the two parties. By the end of 2024, the first cooperation project will achieve the transformation of scleral lens overseas technology in China and domestic large-scale production; In 2025, it is expected to achieve an annual output value of 600 million yuan, an annual tax payment of over 60 million yuan, and maintain an annual growth rate of over 30%.
Epicon will also gradually introduce more international advanced ophthalmic products from Capricornia, including defocus soft lenses, soft astigmatism, and multifocal contact lenses. Equipped with globally leading automated production equipment, Epicon will leverage China's strong market and supply chain capabilities, innovate and manufacture, face the world, and strive to become a globally renowned ophthalmic giant.